Adipotide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic peptide designed to destroy blood vessels feeding white fat, binding prohibitin to trigger endothelial cell death, marketed for rapid fat loss. The case rests entirely on animal studies; there is no human trial evidence. The headline concern is dose-dependent kidney toxicity, documented in primates, with no long-term human safety data. Not an approved drug; human use relies on unregulated products sold online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Adipotide (also known as FTPP or Prohibitin-TP01) is an experimental compound that takes a unique approach to fat loss: rather than suppressing appetite or boosting metabolism, it selectively targets and destroys the blood vessels that supply fat tissue, causing fat cells to die from lack of blood flow. Developed at MD Anderson Cancer Center, it contains a "homing" sequence that finds fat tissue blood vessels and a "kill" sequence that destroys them from the inside. The human trial was terminated; its publicly recorded reason does not establish a toxicity-related cause.
How it works in the body
Carries a cell-death signal (a sequence called KLAKLAK) directly to blood vessels feeding fat tissue. It binds to prohibitin on fat tissue blood vessels, gets absorbed into those endothelial cells, then destroys their mitochondria — causing the blood vessels (and the fat they feed) to die.
Research overview
Adipotide works by binding to a protein called prohibitin on the surface of blood vessel cells within fat tissue. Once attached, it is pulled inside the cell where its second component disrupts the cell's mitochondria, triggering cell death and cutting off blood supply to surrounding fat. In mouse studies, daily injections completely reversed diet-induced obesity within 27 days. A landmark 2011 primate study published in Science Translational Medicine showed obese monkeys lost 7-20% of body weight, with total body fat decreasing by nearly 39% and significant improvements in insulin resistance. Notably, lean animals showed no weight loss at the same doses. A Phase 1 human trial began in 2012 in obese prostate cancer patients, but the trial was later terminated; a toxicity-related reason has not been publicly established. No human results were ever published.
Who researches Adipotide?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People exploring muscle growth and performance
Researched for potential effects on lean mass, strength, or athletic performance.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(13)
Rated by level of concern
Dose-dependent renal tubular toxicity observed in primates
HighPMID 22072637 (full text PMC3666164); ClinicalTrials.gov NCT01262664
Elevated serum creatinine indicating kidney stress (reversible upon cessation in animal studies)
ModeratePMID 22072637 (full text PMC3666164)
Mild to marked glucosuria (glucose in urine)
ModeratePMID 22072637 (full text PMC3666164)
Mild to moderate proteinuria (protein in urine)
ModeratePMID 22072637 (full text PMC3666164)
Decreased serum phosphorus and potassium levels
ModeratePMID 22072637 (full text PMC3666164)
Increased urinary renal epithelial cells indicating tubular damage
ModeratePMID 22072637 (full text PMC3666164)
Histological findings of minimal-to-mild tubular degeneration and single-cell necrosis in kidneys
ModeratePMID 22072637 (full text PMC3666164)
Mild dehydration at higher doses
ModeratePMID 22072637 (full text PMC3666164)
Injection site reactions
LowMechanism-based; no primary-source quantification located in PMID 22072637, PMID 15133506, PMID 20103704, or NCT01262664
Fatigue reported in some preclinical observations
TheoreticalNo primary source located; NCT01262664 has no posted results
No long-term human safety data available — all safety data from animal studies only
HighClinicalTrials.gov NCT01262664 (API v2 record: status Terminated, 'Terminated per PI's request', actual enrollment 4, no results posted)
Potential off-target vascular effects in non-adipose tissues not fully characterized
ModeratePMID 15133506 (Nat Med 2004); PMID 22072637 (full text PMC3666164)
Not approved for human use — any human use is entirely experimental and unregulated
HighClinicalTrials.gov NCT01262664; no FDA or EMA approval on record
Interaction summary(8)
Rated by direction with this peptide
Nephrotoxic drugs (aminoglycosides, amphotericin B, cisplatin, high-dose vancomycin, calcineurin inhibitors)
CautionHighAdipotide's dose-limiting toxicity is proximal tubular injury, so co-exposure to agents that damage the same nephron segment risks additive and potentially non-reversible kidney damage. No human interaction data exist; this is mechanism-based extrapolation from the primate renal findings.
Mechanism-based, grounded in the dose-dependent primate renal toxicity in PMID 22072637 (full text PMC3666164)
NSAIDs (ibuprofen, naproxen, ketorolac)
CautionModerateNSAIDs blunt prostaglandin-mediated renal perfusion, which compounds adipotide-associated tubular injury and the dehydration observed at higher doses. Mechanism-based, no human data.
Mechanism-based; established NSAID renal pharmacology plus the tubular injury and dehydration in PMID 22072637
Loop and thiazide diuretics
CautionModerateAdipotide produced dehydration at higher doses and mild-to-moderate falls in serum potassium and phosphorus in primates; diuretics would amplify both the electrolyte wasting and the prerenal insult. Mechanism-based, no human data.
PMID 22072637 (full text PMC3666164: dehydration, decreased serum potassium and phosphorus)
ACE inhibitors and ARBs
CautionModerateLoss of efferent arteriolar tone during adipotide-associated volume depletion can precipitate an acute drop in GFR on top of existing tubular injury. Entirely mechanism-based - no interaction has been studied.
Mechanism-based; standard RAAS-blockade renal hemodynamics plus volume depletion in PMID 22072637
Iodinated contrast media
CautionModerateContrast-associated nephropathy affects the same proximal tubule that adipotide injures, so contrast imaging during or shortly after exposure adds a second insult to the same tubule. Mechanism-based, no human data.
Mechanism-based; contrast nephropathy pathophysiology plus the renal findings in PMID 22072637
Insulin and insulin secretagogues (sulfonylureas, meglitinides)
CautionModerateAdipotide reduced insulin AUC by 36.2% (P=0.019) in obese monkeys and improved glucose tolerance in rodents independently of weight and food intake, so unchanged secretagogue or insulin doses could drive hypoglycemia. Animal data only; no human dosing experience.
PMID 22072637 (full text PMC3666164); PMC3425411 (Diabetes 2012;61:2299-2310, weight- and food-intake-independent glucose tolerance)
SGLT2 inhibitors (empagliflozin, dapagliflozin)
CautionModerateBoth produce glucosuria and osmotic volume loss, so the combination worsens dehydration and makes adipotide's glucosuria useless as an early warning sign of tubular injury. Mechanism-based.
Mechanism-based; dose-dependent mild-to-marked glucosuria reported in PMID 22072637
Renally cleared drugs with a narrow safety margin (lithium, digoxin, metformin)
CautionModerateFalling renal function during treatment can raise levels of drugs dependent on renal clearance; metformin is not narrow-therapeutic-index in the classic sense but carries an added lactic-acidosis concern in acute kidney injury. Mechanism-based extrapolation from the primate renal impairment.
Mechanism-based; dose-dependent renal impairment documented in PMID 22072637
Known risks(13)
Dose-dependent renal tubular toxicity observed in primates
Elevated serum creatinine indicating kidney stress (reversible upon cessation in animal studies)
Mild to marked glucosuria (glucose in urine)
Mild to moderate proteinuria (protein in urine)
Decreased serum phosphorus and potassium levels
Increased urinary renal epithelial cells indicating tubular damage
Histological findings of minimal-to-mild tubular degeneration and single-cell necrosis in kidneys
Mild dehydration at higher doses
Injection site reactions
Fatigue reported in some preclinical observations
No long-term human safety data available — all safety data from animal studies only
Potential off-target vascular effects in non-adipose tissues not fully characterized
Not approved for human use — any human use is entirely experimental and unregulated
Drug interactions(4)
Nephrotoxic drugs (NSAIDs, aminoglycosides, cisplatin, etc.)
High (theoretical)Given adipotide's dose-dependent renal tubular toxicity, concomitant use with other nephrotoxic agents would be expected to increase risk of kidney damage. This was a theoretical concern noted in preclinical assessment.
Anticoagulants / Antiplatelets
Moderate (theoretical)Adipotide causes vascular disruption and endothelial cell apoptosis. Concurrent anticoagulant use could theoretically increase bleeding risk at sites of vascular damage.
Antihypertensives / Diuretics
Moderate (theoretical)Adipotide was associated with dehydration and electrolyte changes (decreased phosphorus and potassium). Diuretics or antihypertensives could exacerbate these effects.
Other weight loss medications
No formal interaction studies conducted. Combining with GLP-1 agonists or other anti-obesity agents could potentially cause excessive weight loss or compounding metabolic stress.
Research & benefits
Evidence base
- Total Studies
- 12
- Human Studies
- 1
Strong preclinical evidence in mice and nonhuman primates. A single Phase 1 human trial (NCT01262664) was initiated in 2012 at MD Anderson Cancer Center in obese patients with castrate-resistant prostate cancer. The trial evaluated five dose levels across a 28-day subcutaneous injection cycle. No human results have been published. The trial was terminated at the principal investigator's request; a toxicity-related reason was not established.
Researched for(8)
Rated by confidence in the evidence
Rapid weight loss in animal models (7.4-14.7% body weight reduction in 28 days in primates)
LowTreated primates lost 7.4 to 14.7% body weight over 28 days; no human data exist.
PMID 22072637 (Sci Transl Med 2011;3:108ra112, full text PMC3666164) only
Selective targeting of white adipose tissue vasculature without affecting lean body mass
LowMechanism confirmed in mice and primates; lean mass sparing is a secondary, less rigorous endpoint.
PMID 15133506 (Nat Med 2004); PMID 22072637
Marked improvement in insulin resistance (insulin AUC decreased 36% in obese primates)
LowIn obese monkeys, adipotide lowered insulin AUC by 36% after four weeks of treatment.
PMID 22072637 (Barnhart et al., Sci Transl Med 2011;3(108):108ra112, full text PMC3666164) — the primary source; it reports a 36.2% mean decrease in insulin AUC in obese rhesus monkeys after 28 days of adipotide. The dose-finding experiment reported insulin AUC decreases of 61.4% and 63.5% in two monkeys; these are separate from the 36.2% mean decrease in the fixed-dose experiment.
Reduction in total body fat by approximately 38.7% in treated primates vs 14.8% in controls
SpeculativeSingle primate study; controls also lost 14.8% fat, so the treatment effect is smaller than it appears.
PMID 22072637 (full text PMC3666164)
Decreased abdominal circumference and BMI in obese primates
SpeculativeSingle small primate study: BMI fell 3.7 to 17.3% and waist size 6.5 to 14.3% in most treated animals.
PMID 22072637 (full text PMC3666164)
No weight loss effect in lean animals, suggesting selectivity for excess adipose tissue
LowConfirmed in rodents and lean primates; supports a fat-selective mechanism, but evidence is animal-only.
PMID 20103704 (Diabetes 2010;59:907-915); PMID 22072637 (full text PMC3666164)
Preserved lean body mass during treatment in long-term mouse studies
SpeculativeFat and lean mass were directly measured by nuclear magnetic resonance; the longer experiment lasted 27 days, so it does not establish long-term preservation.
PMID 20103704 (Kim, Woods & Seeley, Diabetes 2010) — fat and lean mass were directly measured by nuclear magnetic resonance in experiments lasting 4 or 27 days, so this does not establish long-term lean-mass preservation; the mechanistic basis for lean-mass sparing comes from adipotide's fat-selective vascular targeting rather than a quantified finding in this paper.
Distinct vascular-targeting mechanism versus GLP-1 agonists or metabolic modulators
LowTargets fat-tissue vasculature via apoptosis, not receptors, but still reduces food intake in rodents.
PMID 15133506 (Nat Med 2004, 10:625-32); PMID 20103704 (Diabetes 2010;59:907-915)
Benefits(8)
Rapid weight loss in animal models (7.4-14.7% body weight reduction in 28 days in primates)
Selective targeting of white adipose tissue vasculature without affecting lean body mass
Marked improvement in insulin resistance (insulin AUC decreased 36% in obese primates)
Reduction in total body fat by approximately 38.7% in treated primates vs 14.8% in controls
Decreased abdominal circumference and BMI in obese primates
No weight loss effect in lean animals, suggesting selectivity for excess adipose tissue
Preserved lean body mass during treatment in long-term mouse studies
Distinct vascular-targeting mechanism versus GLP-1 agonists or metabolic modulators
Key studies(4)
Barnhart KF, Christianson DR, Hanley PW, et al.
Science Translational Medicine
2011
Obese rhesus monkeys treated with adipotide at 0.43 mg/kg SC daily for 28 days lost 7.4-14.7% body weight. Total body fat decreased 38.7%. Insulin AUC decreased 36.2-63.5%. MRI and DEXA confirmed white adipose tissue reduction. Reversible renal tubular injury was the primary adverse effect.
Kim DH, Woods SC, Seeley RJ
Diabetes
2010
Daily SC injections at 3 mg/kg in mice completely reversed high-fat-diet-induced obesity within 27 days. 76% of mass reduction was from reduced caloric intake. Fat loss was the primary component while lean mass was preserved. No conditioned taste aversion or central nervous system toxicity observed.
MD Anderson Cancer Center / Arrowhead Research Corporation
ClinicalTrials.gov
2012
Phase 1 trial evaluating 28-day subcutaneous injection cycle across five dose levels in obese patients with castrate-resistant prostate cancer. Endpoints included maximum tolerated dose, pharmacokinetics, weight change, and disease progression. No results published; trial discontinued.
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W
Nature Medicine
2004
Original discovery paper demonstrating that the CKGGRAKDC-GG-D(KLAKLAK)2 peptide selectively homes to white adipose tissue vasculature via prohibitin binding and induces apoptosis in adipose endothelial cells, causing rapid weight loss in obese mice.
Regulation & availability
Why researchers look at it
The 2011 primate study in Science Translational Medicine showed obese monkeys lost 7-20% of body weight with a 39% reduction in total body fat — by selectively destroying blood vessels that feed fat tissue rather than suppressing appetite. The human trial was terminated, but a toxicity-related reason has not been established, and no human trial results were ever published. The vascular-targeting approach may yet inform future anti-obesity strategies.
- Estimated cost
- Phase 1 trial terminated; no results posted.
- FDA status
- Adipotide is not FDA-approved and is not eligible for compounding in the US. NCT01262664 was subsequently terminated at the principal investigator's request, with no results posted.
- WADA status
- Not specifically named on the WADA Prohibited List. However, as an unapproved experimental compound, it would likely fall under WADA S0 (Non-Approved Substances) category, which prohibits any pharmacological substance not addressed by other sections of the Prohibited List and with no current approval by any governmental regulatory health authority for human therapeutic use. Athletes should consider it prohibited.
- Prescribability
- No
- Availability
- Not approved for human use by any regulatory agency. Not prescribed or legally sold for human consumption. Clinical development discontinued ~2019.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(7)
- 2004Original discovery published in Nature Medicine by Kolonin, Pasqualini, and Arap at UT/MD Anderson, demonstrating prohibitin-targeting peptide causes rapid weight loss in obese mice
- 2010Kim, Woods, and Seeley publish expanded mouse study in Diabetes showing adipotide reverses diet-induced obesity and reduces food intake through novel adipose-vascular signaling
- 2011Landmark primate study published in Science Translational Medicine by Barnhart et al. demonstrating 11% average weight loss in obese rhesus monkeys over 28 days with improved insulin resistance
- 2012-01-04Arrowhead announces FDA acceptance of the IND permitting a Phase 1 adipotide trial at MD Anderson.
- 2012-07First patient dosed in Phase 1 clinical trial (NCT01262664) at MD Anderson Cancer Center in obese patients with castrate-resistant prostate cancer
- ~2019Phase 1 trial terminated. No human efficacy or safety results published. The recorded termination reason is the principal investigator's request; a toxicity-related explanation was not established.
- 2026Remains an experimental research compound only. Not approved by FDA or any regulatory authority. No active clinical trials.
Sources & FAQs
Research sources(5)
- A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
- Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight
- NCT01262664 - Phase 1 Trial of Adipotide
- Prohibitin-targeting peptide 1
- Targeted killing of endothelial cells by a proapoptotic peptide (Kolonin et al. 2004)
Frequently asked questions(5)
What is Adipotide and how does it work?
Adipotide (FTPP) is an experimental peptidomimetic that targets blood vessels supplying white adipose tissue. Its homing sequence (CKGGRAKDC) binds prohibitin and ANXA2 receptors on fat tissue blood vessel endothelial cells, while the proapoptotic sequence D(KLAKLAK)2 disrupts their mitochondria, causing programmed cell death. This starves fat cells of blood supply, leading to fat tissue reduction.
Is Adipotide approved for human use?
No. Adipotide is not approved by the FDA or any regulatory authority for human use. A Phase 1 clinical trial was initiated in 2012 but the trial was subsequently terminated at the principal investigator's request. It remains an experimental research compound only.
What were the results in animal studies?
In obese rhesus monkeys, 28 days of treatment produced 7-15% body weight loss, 38.7% reduction in total body fat, and 36-64% improvement in insulin resistance. In mice, it completely reversed diet-induced obesity within 27 days. Lean animals showed no weight loss, suggesting selectivity for excess fat.
Why was Adipotide clinical development stopped?
The registry records termination at the principal investigator's request, without establishing a toxicity-related reason. Primate studies documented renal tubular toxicity. No results are posted in the registry.
How is Adipotide different from GLP-1 agonists like semaglutide?
Unlike GLP-1 receptor agonists that suppress appetite centrally, Adipotide works by directly destroying blood vessels feeding white adipose tissue, causing fat cell death through ischemic apoptosis. It represents a fundamentally different mechanism targeting the vasculature rather than appetite or metabolic pathways.